Galecto Inc. (GLTO): Price and Financial Metrics

Galecto Inc. (GLTO): $0.72

0.01 (-0.76%)

POWR Rating

Component Grades








Add GLTO to Watchlist
Sign Up

Industry: Biotech




#219 of 356

in industry

GLTO Price/Volume Stats

Current price $0.72 52-week high $3.70
Prev. close $0.73 52-week low $0.54
Day low $0.69 Volume 537,200
Day high $0.75 Avg. volume 285,401
50-day MA $1.33 Dividend yield N/A
200-day MA $1.91 Market Cap 19.51M

GLTO Stock Price Chart Interactive Chart >

Galecto Inc. (GLTO) Company Bio

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

GLTO Latest News Stream

Event/Time News Detail
Loading, please wait...

GLTO Latest Social Stream

Loading social stream, please wait...

View Full GLTO Social Stream

Latest GLTO News From Around the Web

Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.

Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls

Today's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly.

Yahoo | September 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

Galecto Announces Plans to Explore Strategic Alternatives

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Galecto

Yahoo | September 26, 2023

Galecto to Present at Investor Conferences in September

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings. H.C. Wainwright 25th Annual Global Investment ConferenceDate

Yahoo | August 31, 2023

OrbiMed Advisors LLC Reduces Stake in Galecto Inc

Firm real-time pick highlight

Yahoo | August 17, 2023

Read More 'GLTO' Stories Here

GLTO Price Returns

1-mo 22.03%
3-mo N/A
6-mo -66.51%
1-year -61.90%
3-year N/A
5-year N/A
YTD -37.39%
2022 -62.05%
2021 -75.78%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!